[{"orgOrder":0,"company":"Emmecell","sponsor":"Emmecell","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EO2002","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Emmecell \/ Emmecell","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Emmecell"},{"orgOrder":0,"company":"Emmecell","sponsor":"Emmecell","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EO2002","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Emmecell \/ Emmecell","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Emmecell"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EO2002","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Inapplicable"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EO2002","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmecell \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Emmecell

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : EO2002,Ripasudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Recipient : Asociación para Evitar la Ceguera en México

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : EO2002,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Study Phase : Phase I

                          Recipient : Asociación para Evitar la Ceguera en México

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          October 19, 2022

                          Lead Product(s) : EO2002,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Recipient : Asociación para Evitar la Ceguera en México

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          May 20, 2021

                          Lead Product(s) : EO2002,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The active IND enables Emmecell to initiate a Phase 1 clinical trial designed to assess the tolerability, safety, and efficacy of EO2002 in patients with corneal edema.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 22, 2020

                          Lead Product(s) : EO2002,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 10, 2019

                          Lead Product(s) : EO1404,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Recipient : Valeria Sanchez-Huerta

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank